Open AccessCabozantinib as an emerging treatment for sarcoma
Author(s) -
Patrick Schöffski,
JeanYves Blay,
Isabelle RayCoquard
Publication year - 2020
Publication title -
current opinion in oncology/current opinion in oncology, with cancerlit
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.297
H-Index - 95
eISSN - 1080-8140
pISSN - 1040-8746
DOI - 10.1097/cco.0000000000000644
Subject(s) - cabozantinib , medicine , sarcoma , gist , oncology , tyrosine kinase inhibitor , osteosarcoma , cancer research , medullary thyroid cancer , soft tissue sarcoma , imatinib , clinical trial , axitinib , stromal cell , sunitinib , renal cell carcinoma , pathology , cancer , thyroid cancer , myeloid leukemia
Sarcomas are a diverse group of rare solid tumors with limited treatment options for patients with advanced, inoperable disease. Cabozantinib is a tyrosine kinase inhibitor currently approved for advanced renal cell, hepatocellular, and medullary thyroid carcinoma. Cabozantinib has potent activity against a variety of kinases, including MET, vascular endothelial growth factor receptor, and AXL, that are associated with sarcoma growth and development. Here we review the preclinical findings and clinical development of cabozantinib in the treatment of soft tissue sarcoma, gastrointestinal stromal tumors (GIST), osteosarcoma, and Ewing sarcoma.